Genus plc (LON:GNS – Get Free Report) insider Celia Baxter purchased 2,336 shares of the company’s stock in a transaction on Friday, June 26th. The stock was acquired at an average cost of GBX 2,140 per share, for a total transaction of £49,990.40.
Genus Price Performance
Genus stock opened at GBX 2,138.24 on Monday. The stock has a market capitalization of £1.42 billion, a price-to-earnings ratio of 30.12, a PEG ratio of 2.87 and a beta of 0.90. Genus plc has a 52-week low of GBX 1,972 and a 52-week high of GBX 3,220. The stock’s 50 day moving average price is GBX 2,324.17 and its two-hundred day moving average price is GBX 2,587.02. The company has a debt-to-equity ratio of 51.73, a quick ratio of 1.08 and a current ratio of 2.25.
Wall Street Analyst Weigh In
Separately, Berenberg Bank reissued a “buy” rating and set a GBX 3,350 target price on shares of Genus in a research note on Monday, May 11th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of GBX 3,216.67.
Genus Company Profile
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.
Featured Stories
- Five stocks we like better than Genus
- Winnebago Misses Estimates, But Surges 14% After Earnings
- As Stablecoins Keep Growing, These 2 Stocks Benefit
- Apple Just Handed These 4 Memory Stocks Their Best News of the Year
- Costco’s Secret Growth Engine May Be Running Out of Gas
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.
